Company / SG&A Expense
Ligand Pharmaceuticals, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$92.4M
FY2025
5-year range
$46.8M / $92.4M
FY2021-FY2025
Trend
+17.5%
vs FY2024
Sector context
#116 of 213
Health Care
What the data says
At $92M, Ligand Pharmaceuticals, Inc.'s sg&a expense ranks #98 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $28M in FY2016 to $92M in FY2025.
Based on SEC 10-K filings.
$92M in FY2025 with a 5-year CAGR of +9.0%.
Increased from $53M to $92M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.7%
- 5-Year CAGR
- +9.0%
- 10-Year CAGR
- -
Sector benchmark
#98 of 213 in Health CareTop 46% of 213This company $92.4M Sector average $722.3M
▼
-87.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 17.5% year-over-year.
- Ranks #116 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $92.4M | +17.5% |
| FY2024 | $78.7M | +49.0% |
| FY2023 | $52.8M | -24.7% |
| FY2022 | $70.1M | +49.7% |
| FY2021 | $46.8M | -22.0% |
| FY2020 | $60.0M | +43.3% |
| FY2019 | $41.9M | +11.0% |
| FY2018 | $37.7M | +31.7% |
| FY2017 | $28.7M | +3.6% |
| FY2016 | $27.7M | +8.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026